Andere talen Capricor Therapeutics, Inc.

Aandelen

CAPR

US14070B3096

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 10-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
5,3 ^USD	-2,21%		-3,11%	+8,38%

09/05	Capricor Therapeutics, Inc. presenteert updates van het Exosome-platform op de 27e jaarlijkse bijeenkomst van de American Society of Gene and Cell Therapy	CI
29/04	Transcript : Capricor Therapeutics, Inc. - Special Call

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Capricor Therapeutics to Present Exosome Platform Updates at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting	09/05
Capricor Therapeutics, Inc. to Present Exosome Platform Updates At the American Society of Gene and Cell Therapy 27Th Annual Meeting	09/05
Capricor Therapeutics to Present at Upcoming Scientific and Medical Conferences	08/05
Capricor Therapeutics to Present First Quarter 2024 Financial Results and Recent Corporate Update on May 13	06/05
Capricor Therapeutics Gets Another Type-B Meeting With FDA for Duchenne Muscular Dystrophy Investigational Drug	24/04
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy	24/04
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy	24/04
Capricor Therapeutics to Present at Upcoming Investor Conferences	21/03
Capricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference	06/03
Capricor Therapeutics, Inc. to Present Positive 24-Month Results from its HOPE-2 Open-Label Extension Study at 2024 Muscular Dystrophy Association Clinical & Scientific Conference	06/03
Capricor: Q4 Earnings Snapshot	29/02
Earnings Flash (CAPR) CAPRICOR THERAPEUTICS Posts Q4 Revenue $12.1M, vs. Street Est of $10.6M	29/02
Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	29/02
Capricor Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/02
Capricor Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
Sector Update: Health Care Stocks Ease Late Afternoon	27/02
Sector Update: Health Care Stocks Decline Tuesday Afternoon	27/02
Capricor Secures Meeting With FDA on CAP-1002 Manufacturing Plans; Shares Rise	27/02
Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy	27/02
Capricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29	22/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Capricor Therapeutics, Inc.

Aandelen

CAPR

US14070B3096

Andere talen

Filters